MedPath

Telavant, Inc.

Telavant, Inc. logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
2022-01-01
Employees
11
Market Cap
-
Website
https://www.telavanttx.com

Clinical Trials

4

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:2
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 2
2 (50.0%)

Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease

Phase 2
Withdrawn
Conditions
Crohn Disease
Interventions
Drug: Investigational Product
Drug: Placebo
First Posted Date
2022-07-22
Last Posted Date
2023-10-19
Lead Sponsor
Telavant, Inc.
Registration Number
NCT05471492

Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2020-02-17
Last Posted Date
2023-10-19
Lead Sponsor
Telavant, Inc.
Target Recruit Count
16
Registration Number
NCT04269538
Locations
🇯🇵

P-one Clinic, Hachioji-shi, Tokyo, Japan

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

Phase 2
Completed
Conditions
Colitis, Ulcerative
Interventions
First Posted Date
2016-07-21
Last Posted Date
2023-10-23
Lead Sponsor
Telavant, Inc.
Target Recruit Count
50
Registration Number
NCT02840721
Locations
🇺🇸

Surgery Center of Aventura, Aventura, Florida, United States

🇺🇸

Venture Ambulatory Surgical Center, North Miami Beach, Florida, United States

🇺🇸

FQL Research, LLC, Pembroke Pines, Florida, United States

and more 24 locations

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2013-11-20
Last Posted Date
2023-10-19
Lead Sponsor
Telavant, Inc.
Target Recruit Count
92
Registration Number
NCT01989143
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath